Calidi Biotherapeutics Advances Cancer Immunotherapy Platform with Promising Virotherapy Research
TL;DR
Calidi Biotherapeutics reported a Q1 2025 net loss of $5.0 million, showcasing FDA clearance for CLD-201 and promising Redtail platform data at AACR.
Calidi Biotherapeutics uses allogeneic stem cell-based immunotherapy for solid tumors, with enhanced efficacy and improved patient safety in multiple oncology indications.
Calidi Biotherapeutics' technology empowers the immune system to combat cancer, potentially treating or preventing metastatic disease, making tomorrow better than today.
Calidi Biotherapeutics announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, advancing systemic virotherapies targeting metastatic cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics has demonstrated notable progress in its oncology research, reporting a reduced first quarter net loss of $5.0 million compared to $7.2 million in the previous year. The company's strategic advancements in cancer treatment include receiving FDA clearance for an investigational new drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy targeting solid tumors.
At the American Association for Cancer Research (AACR) conference, the company presented promising data on its Redtail platform, showcasing an innovative approach to delivering IL15 superagonist via an engineered oncolytic virus. This research represents a potentially significant development in cancer treatment, particularly for metastatic diseases.
Key leadership additions, including new CEO Dr. Eric Poma and Chief Medical Officer Dr. Guy Clifton, signal the company's commitment to advancing its systemic virotherapy technologies. Calidi's unique approach involves using potent stem cells to carry oncolytic viruses, with the potential to enhance cancer treatment efficacy and patient safety.
The company's platform aims to develop off-the-shelf, universal cell-based delivery systems designed to protect, amplify, and potentiate oncolytic viruses. This dual approach could offer innovative strategies for treating or potentially preventing metastatic cancer, representing a promising avenue in oncological research.
Curated from InvestorBrandNetwork (IBN)
